Selected parenteral drug doses for infants ≤28 days of age with suspected invasive Staphylococcus aureus infection
References:
- Capparelli EV, Lane JR, Romanowski GL, et al.
The influences of renal function and maturation on vancomycin elimination in
newborns and infants. J Clin Pharmacol, 2001: 41:927.
- Nelson's Pediatric Antimicrobial Therapy, 27th ed, Bradley JS, Nelson JD, Barnett ED, et al (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.100.
- Radu L, Bengry T, Akierman A, et al. Evolution of empiric vancomycin dosing in a neonatal population. J Perinatol. 2018;38:1702.
- Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.Elk Grove Village, IL 2009. p.745.
Data from: American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2021 Report of the Committee on Infectious Diseases, 32
nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.876.